US real-world study evaluates incretin exposure in resmetirom initiators

In a real-world US cohort of resmetirom initiators, over a third had recorded incretin exposure, but among those without prior incretin use, starting an incretin within 30 days of resmetirom was uncommon at about 5%. Among 6837 patients initiating resmetirom, 37.2% had a recorded incretin prescription, mostly before starting resmetirom (33.8%). In patients without incretin use in the prior 5 years, only 5.1% co-initiated an incretin within 30 days of resmetirom. Co-initiators had a higher mean body mass index and higher metformin use, but co-initiation was not clearly associated with diabetes or coded overweight or obesity. Online version: https://www.diabesityrounds.com/a/us-real-world-study-evaluates-incretin-exposure-in-resmetirom-initiators

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24361221
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

US real-world study evaluates incretin exposure in resmetirom initiators

Diabesity Rounds
Zenodo (CERN European Organization for Nuclear Research)
Diabetes Treatment and Management
article

US real-world study evaluates incretin exposure in resmetirom initiators

Diabesity Rounds
article en

Abstract

In a real-world US cohort of resmetirom initiators, over a third had recorded incretin exposure, but among those without prior incretin use, starting an incretin within 30 days of resmetirom was uncommon at about 5%. Among 6837 patients initiating resmetirom, 37.2% had a recorded incretin prescription, mostly before starting resmetirom (33.8%). In patients without incretin use in the prior 5 years, only 5.1% co-initiated an incretin within 30 days of resmetirom. Co-initiators had a higher mean body mass index and higher metformin use, but co-initiation was not clearly associated with diabetes or coded overweight or obesity. Online version: https://www.diabesityrounds.com/a/us-real-world-study-evaluates-incretin-exposure-in-resmetirom-initiators

Zenodo (CERN European Organization for Nuclear Research)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon